OLAPARIB

Brand name:

• Lynparza®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

ASTRAZENECA PTY LTD

Condition/indication:
(therapeutic use)

• Human epidermal growth factor 2 (HER2) negative metastatic breast cancer with a confirmed BRCA1 or BRCA2 mutation

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Other PBAC consideration:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

08/08/2024

Lodgement of required documentation:

16/08/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 26/09/2024

Status:

Finalised

Government processes:

Commenced on 27/09/2024

Medicine listed on the PBS:

01/01/2025 (see PBS schedule)